← Eichor
Study identifier: NCT06290427 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)

Condition: Renal Carcinoma  ·  Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

The Urology Unit of AOUI Verona proposes a clinical study aimed at a preliminary evaluation of postoperative complications specifically focused on robotic partial nephrectomy (RAPN) procedures using two currently available platforms: * DaVinci®; * Hugo®. The questions it aims to answer are: Does the estimation of the post-operative complications suggest something? Are differences (intra- and post-operative, oncological, functional, technical, and economic) among the three intervention approaches observable? Participants will be invited to join one of these two experimental group: 1. surgery with the DaVinci platform; 2. surgery with the Hugo platform.

This description comes directly from the study's public registry record.

Talk to the study team

Alessandro AA Antonelli, MD  ·  +39 0458127701  ·  alessandro.antonelli@aovr.veneto.it

Always discuss trial participation with your own doctor first.

Locations (1)

Urology Unit, AOUI VeronaVerona, VR, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06290427